Amova Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN

Amova Asset Management Americas Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 5.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 917,246 shares of the life sciences company’s stock after acquiring an additional 49,265 shares during the period. Amova Asset Management Americas Inc. owned about 0.60% of Illumina worth $87,028,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Assetmark Inc. lifted its position in Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the period. Versant Capital Management Inc raised its stake in shares of Illumina by 8.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after buying an additional 111 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the period. Archer Investment Corp boosted its stake in shares of Illumina by 12.9% in the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after buying an additional 123 shares in the last quarter. Finally, Callan Family Office LLC grew its holdings in Illumina by 4.4% during the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after acquiring an additional 124 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is owned by company insiders.

Illumina Stock Down 0.5%

Shares of NASDAQ:ILMN opened at $128.97 on Thursday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a market cap of $19.72 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 2.48 and a beta of 1.45. The stock’s 50-day moving average price is $134.74 and its two-hundred day moving average price is $118.89. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the firm posted $0.95 EPS. The company’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ILMN shares. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. JPMorgan Chase & Co. cut their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Stifel Nicolaus boosted their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Evercore set a $150.00 target price on shares of Illumina in a report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $129.69.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.